348150 — KoBioLabs Balance Sheet
0.000.00%
- KR₩100bn
- KR₩79bn
- KR₩68bn
Annual balance sheet for KoBioLabs, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 50,975 | 86,681 | 92,856 | 66,160 | 55,689 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5,228 | 3,693 | 5,175 | 5,312 | 3,780 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 57,810 | 98,619 | 102,478 | 75,729 | 66,682 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 383 | 5,791 | 20,485 | 34,858 | 31,172 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 58,537 | 105,285 | 123,930 | 114,623 | 102,096 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3,089 | 6,840 | 8,944 | 21,151 | 13,822 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 3,146 | 14,697 | 46,607 | 69,672 | 64,177 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 55,391 | 90,589 | 77,323 | 44,951 | 37,919 |
Total Liabilities & Shareholders' Equity | 58,537 | 105,285 | 123,930 | 114,623 | 102,096 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |